IntelliPharmaCeutics Intl Stock Price, News & Analysis (NASDAQ:IPCI)

$0.74 -0.01 (-1.33 %)
(As of 12/14/2017 01:45 PM ET)
Previous Close$0.75
Today's Range$0.70 - $0.76
52-Week Range$0.70 - $3.12
Volume341,300 shs
Average Volume305,684 shs
Market Capitalization$26.08 million
P/E RatioN/A
Dividend YieldN/A
Beta0.99

About IntelliPharmaCeutics Intl (NASDAQ:IPCI)

IntelliPharmaCeutics Intl logoIntellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

Receive IPCI News and Ratings via Email

Sign-up to receive the latest news and ratings for IPCI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IPCI
CUSIPN/A
Phone416-798-3001

Debt

Debt-to-Equity RatioN/A
Current Ratio0.52%
Quick Ratio0.48%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.25 million
Price / Sales11.42
Cash FlowN/A
Price / CashN/A
Book Value$0.04 per share
Price / Book18.50

Profitability

Trailing EPS($0.35)
Net Income$-10,140,000.00
Net Margins-205.34%
Return on Equity-2,062.11%
Return on Assets-135.25%

Miscellaneous

Employees54
Outstanding Shares34,710,000

IntelliPharmaCeutics Intl (NASDAQ:IPCI) Frequently Asked Questions

What is IntelliPharmaCeutics Intl's stock symbol?

IntelliPharmaCeutics Intl trades on the NASDAQ under the ticker symbol "IPCI."

How were IntelliPharmaCeutics Intl's earnings last quarter?

IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) announced its quarterly earnings data on Thursday, October, 13th. The company reported ($0.07) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.07). The firm earned $0.56 million during the quarter, compared to analysts' expectations of $0.50 million. IntelliPharmaCeutics Intl had a negative net margin of 205.34% and a negative return on equity of 2,062.11%. View IntelliPharmaCeutics Intl's Earnings History.

When will IntelliPharmaCeutics Intl make its next earnings announcement?

IntelliPharmaCeutics Intl is scheduled to release their next quarterly earnings announcement on Friday, February, 9th 2018. View Earnings Estimates for IntelliPharmaCeutics Intl.

Where is IntelliPharmaCeutics Intl's stock going? Where will IntelliPharmaCeutics Intl's stock price be in 2017?

3 equities research analysts have issued 12 month price objectives for IntelliPharmaCeutics Intl's stock. Their forecasts range from $2.00 to $3.10. On average, they expect IntelliPharmaCeutics Intl's share price to reach $2.37 in the next twelve months. View Analyst Ratings for IntelliPharmaCeutics Intl.

What are Wall Street analysts saying about IntelliPharmaCeutics Intl stock?

Here are some recent quotes from research analysts about IntelliPharmaCeutics Intl stock:

  • 1. According to Zacks Investment Research, "Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada. " (12/13/2017)
  • 2. Maxim Group analysts commented, "We note the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committees will hold discussions on the new drug application for Intellipharmaceutics’ abuse- deterrent oxycodone hydrochloride extended-release oral tablets (Rexista) on July 26, 2017. The committees will discuss the overall risk-benefit profile of Rexista and evaluate whether the abuse-deterrent properties of Rexista will be sufficient to support labeling." (7/21/2017)
  • 3. Aegis analysts commented, "We believe the stay is more likely to last longer than 30 months, as is typical in most patent dispute cases." (4/18/2017)

Who are some of IntelliPharmaCeutics Intl's key competitors?

Who are IntelliPharmaCeutics Intl's key executives?

IntelliPharmaCeutics Intl's management team includes the folowing people:

  • Isa Odidi Ph.D., Chairman of the Board, Chief Executive Officer
  • Amina Odidi Ph.D., President, Chief Operating Officer, Director
  • Andrew Patient, Chief Financial Officer
  • John N. Allport, Vice President - Legal Affairs and Licensing, Secretary, Director
  • Patrick N. Yat Ph.D., Vice President - Pharmaceutical Analysis and Chemistry
  • Kenneth Keirstead, Independent Director
  • Bahadur Madhani, Independent Director
  • Eldon R. Smith M.D., Independent Director (Age 75)

How do I buy IntelliPharmaCeutics Intl stock?

Shares of IntelliPharmaCeutics Intl can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IntelliPharmaCeutics Intl's stock price today?

One share of IntelliPharmaCeutics Intl stock can currently be purchased for approximately $0.74.

How big of a company is IntelliPharmaCeutics Intl?

IntelliPharmaCeutics Intl has a market capitalization of $26.08 million and generates $2.25 million in revenue each year. The company earns $-10,140,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. IntelliPharmaCeutics Intl employs 54 workers across the globe.

How can I contact IntelliPharmaCeutics Intl?

IntelliPharmaCeutics Intl's mailing address is 30 WORCESTER ROAD, TORONTO A6, M9W 5X2. The company can be reached via phone at 416-798-3001 or via email at [email protected]


MarketBeat Community Rating for IntelliPharmaCeutics Intl (IPCI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  191 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  317
MarketBeat's community ratings are surveys of what our community members think about IntelliPharmaCeutics Intl and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

IntelliPharmaCeutics Intl (NASDAQ:IPCI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.672.67
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.78$3.78$4.00$5.33
Price Target Upside: 273.76% upside273.76% upside60.64% upside151.57% upside

IntelliPharmaCeutics Intl (NASDAQ:IPCI) Consensus Price Target History

Price Target History for IntelliPharmaCeutics Intl (NASDAQ:IPCI)

IntelliPharmaCeutics Intl (NASDAQ:IPCI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/26/2017MackieUpgradeHold$1.00 -> $3.10MediumView Rating Details
7/27/2017Maxim GroupLower Price TargetBuy -> Buy$6.00 -> $2.00HighView Rating Details
4/18/2017AegisReiterated RatingHold$2.00LowView Rating Details
10/17/2016Brean CapitalSet Price TargetBuy$8.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

IntelliPharmaCeutics Intl (NASDAQ:IPCI) Earnings History and Estimates Chart

Earnings by Quarter for IntelliPharmaCeutics Intl (NASDAQ:IPCI)

IntelliPharmaCeutics Intl (NASDAQ IPCI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/9/2018        
10/13/2016Q316($0.07)($0.07)$0.50 million$0.56 millionViewN/AView Earnings Details
7/13/2016Q216($0.09)($0.08)$0.80 million$0.56 millionViewN/AView Earnings Details
4/14/2016Q1($0.07)($0.09)$0.70 million$0.57 millionViewN/AView Earnings Details
10/9/2015Q315($0.05)($0.08)$1.30 million$0.84 millionViewN/AView Earnings Details
7/13/2015Q215($0.05)($0.06)$1.20 million$1.27 millionViewN/AView Earnings Details
4/14/2015Q1 2015($0.08)($0.04)$1.20 million$1.14 millionViewN/AView Earnings Details
2/23/2015Q4 2014($0.07)($0.06)$1.40 million$1.54 millionViewN/AView Earnings Details
10/15/2014Q3($0.05)($0.07)$2.40 million$1.07 millionViewN/AView Earnings Details
4/14/2014Q114$0.11$0.09$4.49 million$4.70 millionViewN/AView Earnings Details
2/18/2014($0.08)($0.31)ViewN/AView Earnings Details
4/3/2013Q113($0.12)($0.07)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

IntelliPharmaCeutics Intl (NASDAQ:IPCI) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.31 EPS
Next Year EPS Consensus Estimate: $-0.32 EPS

Dividends

Dividend History for IntelliPharmaCeutics Intl (NASDAQ:IPCI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for IntelliPharmaCeutics Intl (NASDAQ IPCI)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

IntelliPharmaCeutics Intl (NASDAQ IPCI) News Headlines

Source:
DateHeadline
IntelliPharmaCeutics Intl Inc (IPCI) Expected to Announce Quarterly Sales of $3.25 MillionIntelliPharmaCeutics Intl Inc (IPCI) Expected to Announce Quarterly Sales of $3.25 Million
www.americanbankingnews.com - December 10 at 2:54 AM
$3.25 Million in Sales Expected for Intellipharmaceutics International Inc. (IPCI) This Quarter$3.25 Million in Sales Expected for Intellipharmaceutics International Inc. (IPCI) This Quarter
www.americanbankingnews.com - November 22 at 2:22 AM
-$0.04 Earnings Per Share Expected for Intellipharmaceutics International Inc. (IPCI) This Quarter-$0.04 Earnings Per Share Expected for Intellipharmaceutics International Inc. (IPCI) This Quarter
www.americanbankingnews.com - November 20 at 11:12 PM
 Analysts Expect Intellipharmaceutics International Inc. (IPCI) Will Announce Quarterly Sales of $3.25 Million Analysts Expect Intellipharmaceutics International Inc. (IPCI) Will Announce Quarterly Sales of $3.25 Million
www.americanbankingnews.com - November 19 at 8:26 PM
Head-To-Head Analysis: Intellipharmaceutics International (IPCI) and Its RivalsHead-To-Head Analysis: Intellipharmaceutics International (IPCI) and Its Rivals
www.americanbankingnews.com - November 3 at 7:53 AM
 Analysts Anticipate Intellipharmaceutics International Inc. (IPCI) Will Post Quarterly Sales of $3.25 Million Analysts Anticipate Intellipharmaceutics International Inc. (IPCI) Will Post Quarterly Sales of $3.25 Million
www.americanbankingnews.com - October 29 at 4:02 AM
Reviewing Intellipharmaceutics International (IPCI) and The CompetitionReviewing Intellipharmaceutics International (IPCI) and The Competition
www.americanbankingnews.com - October 27 at 11:48 AM
Intellipharmaceutics International Inc. (IPCI) Short Interest Down 57.7% in SeptemberIntellipharmaceutics International Inc. (IPCI) Short Interest Down 57.7% in September
www.americanbankingnews.com - October 14 at 1:40 AM
Intellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: Q3, 2017 By the Numbers : October 13, 2017Intellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: Q3, 2017 By the Numbers : October 13, 2017
finance.yahoo.com - October 13 at 7:48 PM
New Strong Sell Stocks for October 11th - NasdaqNew Strong Sell Stocks for October 11th - Nasdaq
www.nasdaq.com - October 11 at 9:46 PM
Intellipharmaceutics Announces US$4 Million Registered Direct Offering - GlobeNewswire (press release)Intellipharmaceutics Announces US$4 Million Registered Direct Offering - GlobeNewswire (press release)
globenewswire.com - October 11 at 9:46 PM
Your Daily Pharma Scoop: Alexions Catalysts, Amgens Prolia, Ultragenyx BorosumabYour Daily Pharma Scoop: Alexion's Catalysts, Amgen's Prolia, Ultragenyx Borosumab
seekingalpha.com - October 11 at 4:42 PM
Intellipharmaceutics Announces US$4 Million Registered Direct OfferingIntellipharmaceutics Announces US$4 Million Registered Direct Offering
finance.yahoo.com - October 11 at 4:42 PM
New Strong Sell Stocks for October 11thNew Strong Sell Stocks for October 11th
finance.yahoo.com - October 11 at 4:42 PM
$2.45 Million in Sales Expected for Intellipharmaceutics International Inc. (IPCI) This Quarter$2.45 Million in Sales Expected for Intellipharmaceutics International Inc. (IPCI) This Quarter
www.americanbankingnews.com - October 10 at 7:18 AM
 Brokerages Expect Intellipharmaceutics International Inc. (IPCI) Will Announce Earnings of -$0.04 Per Share Brokerages Expect Intellipharmaceutics International Inc. (IPCI) Will Announce Earnings of -$0.04 Per Share
www.americanbankingnews.com - October 8 at 4:22 PM
Analyzing Intellipharmaceutics International (IPCI) and Its CompetitorsAnalyzing Intellipharmaceutics International (IPCI) and Its Competitors
www.americanbankingnews.com - October 5 at 9:46 AM
DEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses Over $100,000 to Contact the FirmDEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses Over $100,000 to Contact the Firm
finance.yahoo.com - October 2 at 1:05 PM
Intellipharmaceutics International Inc. (IPCI) Given Consensus Rating of "Hold" by BrokeragesIntellipharmaceutics International Inc. (IPCI) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 26 at 12:52 PM
Intellipharmaceutics International Inc. (IPCI) Raised to "Hold" at MackieIntellipharmaceutics International Inc. (IPCI) Raised to "Hold" at Mackie
www.americanbankingnews.com - September 26 at 11:50 AM
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017
finance.yahoo.com - September 25 at 4:41 PM
DEADLINE FRIDAY: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the FirmDEADLINE FRIDAY: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 25 at 4:41 PM
Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDA - GlobeNewswire (press release)Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDA - GlobeNewswire (press release)
globenewswire.com - September 25 at 9:32 AM
Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDAIntellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDA
finance.yahoo.com - September 25 at 9:32 AM
FDA declines to approve Intellipharmas opioid painkillerFDA declines to approve Intellipharma's opioid painkiller
finance.yahoo.com - September 25 at 9:32 AM
Intellipharmaceutics International Inc. (IPCI) Expected to Announce Quarterly Sales of $4.55 MillionIntellipharmaceutics International Inc. (IPCI) Expected to Announce Quarterly Sales of $4.55 Million
www.americanbankingnews.com - September 21 at 1:48 AM
Intellipharmaceutics Announces Receipt of Nasdaq NoticeIntellipharmaceutics Announces Receipt of Nasdaq Notice
finance.yahoo.com - September 20 at 9:28 PM
DEADLINE REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the FirmDEADLINE REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 20 at 9:28 PM
IPCI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Intellipharmaceutics International Inc. and a Lead Plaintiff Deadline of September 29, 2017IPCI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Intellipharmaceutics International Inc. and a Lead Plaintiff Deadline of September 29, 2017
finance.yahoo.com - September 20 at 4:24 PM
INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017
finance.yahoo.com - September 19 at 8:01 PM
ALERT: The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Intellipharmaceutics International Inc. Shareholders and a Lead Plaintiff Deadline of September 29, 2017 (IPCI)ALERT: The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Intellipharmaceutics International Inc. Shareholders and a Lead Plaintiff Deadline of September 29, 2017 (IPCI)
finance.yahoo.com - September 19 at 8:00 PM
10-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm10-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 19 at 8:00 PM
DEADLINE APPROACHING: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the FirmDEADLINE APPROACHING: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 19 at 12:27 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders it Filed a Complaint to Recover Losses Suffered by Investors in Intellipharmaceutics International Inc. and Set a Lead Plaintiff Deadline of September 29, 2017 -- IPCISHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders it Filed a Complaint to Recover Losses Suffered by Investors in Intellipharmaceutics International Inc. and Set a Lead Plaintiff Deadline of September 29, 2017 -- IPCI
finance.yahoo.com - September 18 at 7:25 PM
IPCI EXPANDED CLASS PERIOD: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Intellipharmaceutics International Inc. and a Lead Plaintiff Deadline of September 29, 2017IPCI EXPANDED CLASS PERIOD: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Intellipharmaceutics International Inc. and a Lead Plaintiff Deadline of September 29, 2017
finance.yahoo.com - September 16 at 2:05 AM
DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the FirmDEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 16 at 2:05 AM
EXPANDED CLASS: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Intellipharmaceutics International Inc. and Set a Lead Plaintiff Deadline of September 29, 2017 -- IPCIEXPANDED CLASS: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Investors in Intellipharmaceutics International Inc. and Set a Lead Plaintiff Deadline of September 29, 2017 -- IPCI
finance.yahoo.com - September 15 at 1:51 AM
DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the FirmDEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 15 at 1:51 AM
IPCI EXPANDED CLASS: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Intellipharmaceutics International Inc. and a Lead Plaintiff Deadline of September 29, 2017IPCI EXPANDED CLASS: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Intellipharmaceutics International Inc. and a Lead Plaintiff Deadline of September 29, 2017
finance.yahoo.com - September 14 at 6:30 AM
SHAREHOLDER REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the FirmSHAREHOLDER REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 14 at 6:30 AM
IPCI ALERT: Rosen Law Firm Reminds Intellipharmaceutics International Inc. Investors of Important Deadline in Class Action – IPCIIPCI ALERT: Rosen Law Firm Reminds Intellipharmaceutics International Inc. Investors of Important Deadline in Class Action – IPCI
feeds.benzinga.com - September 13 at 7:43 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in IntelliPharmaCeutics International Inc. of Class Action Lawsuit and Upcoming Deadline - IPCSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in IntelliPharmaCeutics International Inc. of Class Action Lawsuit and Upcoming Deadline - IPC
finance.yahoo.com - September 12 at 10:04 PM
INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017
finance.yahoo.com - September 12 at 4:41 PM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Complaint to Recover Losses Suffered by Investors in Intellipharmaceutics International Inc. and the Lead Plaintiff Deadline of September 29, 2017 -- IPCIEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of a Complaint to Recover Losses Suffered by Investors in Intellipharmaceutics International Inc. and the Lead Plaintiff Deadline of September 29, 2017 -- IPCI
finance.yahoo.com - September 12 at 4:41 PM
UPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the FirmUPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 12 at 4:41 PM
DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the FirmDEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 11 at 8:40 PM
INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Intellipharmaceutics International Inc ... - Business Wire (press release)INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Intellipharmaceutics International Inc ... - Business Wire (press release)
www.businesswire.com - September 10 at 12:21 AM
APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the FirmAPPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 9 at 4:52 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017
finance.yahoo.com - September 8 at 11:52 PM
UPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the FirmUPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 8 at 11:52 PM

SEC Filings

IntelliPharmaCeutics Intl (NASDAQ:IPCI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

IntelliPharmaCeutics Intl (NASDAQ:IPCI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

IntelliPharmaCeutics Intl (NASDAQ IPCI) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.